|Home||Log In||Register||Our Services||My Account||Contact||Help|
|Stockwatch||Level 2||Portfolio||Charts||Research||Share Price||Awards||Stock Screener||Market Scan||Company Zone||Traders' Room|
|Funds||Trades||Terminal||Alerts||Heatmaps||News||Indices||Forward Diary||Forex Prices||Director Deals||Investors' Room|
|CFDs||Shares||SIPPs||ISAs||Forex||ETFs||Videos||Comparison Tables||Spread Betting||Broker Notes||Shares Magazine|
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Wednesday 28 February 2018Venue:
Radisson Blu Hotel Edinburgh, 80 High Street, The Royal Mile, Edinburgh, EH11THEvent Timings:
Registration and coffee
• Ian Griffiths, FD - ANGLE
• Andrew Newland, Chief Executive - ANGLE
• Richard Wolanski, Finance Director - Avation (AVAP)
• Kiran Morzaria, Director & CEO - Cadence Minerals (KDNC)
• Brian Stockbridge, CEO - First Sentinel
• Dave Mutton, COO - PrimaryBid
• Cath O'Neill, CEO - SkinBioTherapeutics
• JJ Traynor, CFO - Sound Energy (SOU)
Drinks reception and canapés
PrimaryBid is a leading FinTech business enabling investors to gain access to fundraisings of companies listed on UK Stock Exchanges. Our unique solution connects the large and active pool of private investors, with companies seeking to raise capital by issuing new shares.
Traditionally, fundraises for listed companies have only been accessible by Institutions and a small number of high net worth investors, PrimaryBid allows all investors to have access to these fundraises at the same time and the same price, delivering open access regardless of the size of their investment. To date over £52m has been sourced via the platform.
ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).
ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.
The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:
· Early detection of cancer;
· Personalised cancer treatment;
· Monitoring of cancer patients during treatment; and
· Post-treatment monitoring of cancer patients in remission.
Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £35 million vested in key assets globally, Cadence is helping us reach tomorrow, today.
First Sentinel is a consortium of companies focused on alternative investments, specializing in equity and debt deals with appealing IRRs, as well as traditional Corporate Finance and Legal Services.
This consortium enables us to support our clients end to end, whether it be the individual investor or corporate offering.
First Sentinel PLC (NEX: FSEN) is an alternative investment company that provides growth capital for public and private company investments. (NEX: FSEN).
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.
Sound Energy plc is a growth focused and private investor centric Moroccan gas explorerlisted on AIM and benefit from: a low cost, multi Tcf potential onshore gas discovery; a strategic partnership with Schlumberger - one of the largest companies in our sector; two supportive cornerstone investors; a potentially transformational drill programme, and a strong retail shareholder base
We are pursuing an onshore gas strategy underpinned by strong gas market fundamentals, which is proving very robust to the current oil price environment and to an increasingly carbon-conscious world. Gas is, rightly, seen as a cleaner alternative to coal and oil.
We are focused on unlocking the Moroccan gas promise, which includes:
De-risking of it’s 31 Tcf exploration potential in Eastern Morocco and up to 9 Tcf in Sidi Moktar through shooting new seismic and aerial gradiometry
Development of it’s existing 0.6 Tcf gas discovery (with first gas targetted for end 2019 / early 2020)